Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13989015 | 0.89 | TRPM8 (0.67) | TRPM8CYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL5439860 | 0.89 | TRPM8 (0.67) | TRPM8CYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL13989012 | 0.89 | TRPM8 (0.67) | TRPM8CYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL4886771 | 0.88 | TRPM8 (0.72) | TRPM8CYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL369792 | 0.88 | TRPM8 (0.72) | TRPM8ALDH1A1NPC1RAB9AEPHX1 | |
| SCHEMBL2628616 | 0.88 | TRPM8 (0.72) | TRPM8ALDH1A1NPC1RAB9AEPHX1 | |
| Acoltremon SCHEMBL23870506 | 0.86 | TRPM8 (1.00) | TRPM8CYP2C19ALDH1A1NPC1RAB9A | |
| Acoltremon SCHEMBL3228667 | 0.86 | TRPM8 (1.00) | TRPM8CYP2C19ALDH1A1NPC1RAB9A | |
| Acoltremon SCHEMBL14811473 | 0.86 | TRPM8 (1.00) | TRPM8CYP2C19ALDH1A1NPC1RAB9A | |
| Acoltremon SCHEMBL16227989 | 0.86 | TRPM8 (1.00) | TRPM8CYP2C19ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300314-A1 | Cooling Compounds | GIVAUDAN SA (CH) | 2008-12-04 | — | — | US | disclosed |
| US-20080300314-A1 | Cooling Compounds | GIVAUDAN SA (CH) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300314-A1 | Cooling Compounds | TAS2R42, TAS2R4, TAS2R41 | TRPM8 73/4885CYP2C19 575/4885ALDH1A1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.